nafamostat has been researched along with Hyperparathyroidism in 1 studies
nafamostat: inhibitor of trypsin, plasmin, pancreatic kallikrein, plasma kallikrein & thrombin; strongly inhibits esterolytic activities of C1r & C1 esterase complement-mediated hemolysis; antineoplastic
Hyperparathyroidism: A condition of abnormally elevated output of PARATHYROID HORMONE (or PTH) triggering responses that increase blood CALCIUM. It is characterized by HYPERCALCEMIA and BONE RESORPTION, eventually leading to bone diseases. PRIMARY HYPERPARATHYROIDISM is caused by parathyroid HYPERPLASIA or PARATHYROID NEOPLASMS. SECONDARY HYPERPARATHYROIDISM is increased PTH secretion in response to HYPOCALCEMIA, usually caused by chronic KIDNEY DISEASES.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nishitani, H | 1 |
| Kim, CW | 1 |
| Yamakawa, M | 1 |
| Nishizawa, Y | 1 |
| Morii, H | 1 |
1 other study available for nafamostat and Hyperparathyroidism
| Article | Year |
|---|---|
[Upper gastrointestinal complications in uremic patients with dialysis].
Topics: Benzamidines; Gastric Mucosa; Gastrointestinal Hemorrhage; Gastrointestinal Neoplasms; Guanidines; H | 1992 |